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Background
Median survival of advanced malignant pleural mesothe-
lioma (MPM) is less than 2 years, and novel treatments
are urgently needed. Immunotherapy with adoptive
T cell transfer is an attractive approach that could be
added to current therapeutic concepts. Fibroblast activa-
tion protein (FAP) is expressed by all subtypes of MPM
[1] and can serve as target of re-directed T cells harbor-
ing an anti-FAP chimeric antigen receptor (CAR) lead-
ing to site-specific T cell activation.
Patients and methods
This is a Phase I study with the primary clinical end-
point of safety and the secondary endpoints of feasibility
and immune monitoring. Immune monitoring includes
measurement of T cell subpopulations, cytokines and
inflammatory parameters. This is the first in human
application of FAP-specific autologous re-directed
T cells in patients with newly diagnosed, inoperable
MPM in the malignant pleural effusion. We report here
on the first patient treated in February 2015. At that
time, he was 74 years old and had received the diagnosis
of MPM in November 2014. After 2 cycles of standard
chemotherapy (Cisplatin/Pemetrexed), 250 ml of periph-
eral blood were collected (day -21), CD 8 T cells
extracted and retro-virally transduced with a FAP-specific
CAR, while the patient was receiving the 3rd cycle of che-
motherapy. On day 0 1x106 CAR T cells were injected
under sterile conditions into the pleural effusion through a
pleural drainage on the intensive care unit (ICU), followed
by 48 hours ICU surveillance. Simultaneously, cytokine
levels were measured in the serum and in the pleural
effusion.
Results
In this first patient, we demonstrated safety and techni-
cal feasibility of the application of re-directed T cells.
No adverse events due to the injection were observed,
in particular no immune-mediated toxicity (e.g. cytokine
storm, inflammation). Ex vivo analysis showed antigen-
specific activity and function of re-directed T cells.
Conclusion
Re-directed T cells against FAP could be a safe and feasi-
ble treatment option for patients with MPM in the
future. Further studies are needed to demonstrate anti-
tumor efficacy.
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